BMY 25282
BMY 25282 (BL 6782) is a mitomycin C (MMC) analog. BMY 25282 catalyzes oxygen activation in hepatocytes. BMY 25282 overcomes MMC tolerance in colon cancer cells and mouse models of colon cancer. BMY 25282 inhibits tumor growth in mouse models of leukemia and melanoma. BMY 25282 can be used in research on cancers such as leukemia, melanoma, and colon cancer[1][2][3].
Product Specifications
CAS Number
88949-01-3
Product Name Alternative
BL 6782
UNSPSC
12352005
Target
Others
Related Pathways
Others
Field of Research
Cancer
Smiles
CO[C@]12N(C[C@H]3[C@@H]2N3)C4=C(C(C(/N=C/N(C)C)=C(C)C4=O)=O)[C@H]1COC(N)=O
Molecular Formula
C18H23N5O5
Molecular Weight
389.41
References & Citations
[1]Silva JM, et al. Contrasting molecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes. Biochem Pharmacol. 1993 Jun 9;45 (11) :2303-9. |[2]Willson JK, et al. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells. Cancer Res. 1985 Nov;45 (11 Pt 1) :5281-6.|[3]Bradner WT, et al. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative. Cancer Res. 1985 Dec;45 (12 Pt 1) :6475-81.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
